Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AngioDynamics, Inc. is a publicly traded medical technology company that designs, manufactures, and sells minimally invasive medical devices used in vascular access, peripheral vascular, and oncology procedures. The company operates within the medical device and healthcare technology industries, serving hospitals, outpatient centers, and physician practices. Its revenue is primarily driven by disposable and capital medical devices used in interventional radiology, vascular surgery, oncology, and critical care settings.
The company is recognized for its focus on clinically differentiated technologies, particularly in image-guided and energy-based therapies. AngioDynamics was founded in 1988 and has evolved from a vascular access–focused business into a broader interventional medical technology company through internal development and targeted acquisitions. Its strategy emphasizes recurring revenue products, physician adoption, and expanding clinical indications.
Business Operations
AngioDynamics organizes its operations into two primary business segments: Med Tech and Med Device. The Med Tech segment includes advanced technology platforms such as irreversible electroporation (IRE) systems and mechanical thrombectomy devices, while the Med Device segment encompasses vascular access products, including peripherally inserted central catheters (PICCs), ports, and dialysis catheters, as well as peripheral vascular products.
The company generates revenue through direct sales in the United States and a combination of direct and distributor-based sales internationally. AngioDynamics controls proprietary device technologies, manufacturing capabilities, and a portfolio of intellectual property supporting its platforms. Notable subsidiaries include AngioDynamics Canada, Inc. and AngioDynamics UK Ltd., supporting international operations. The company has also integrated acquired technologies, such as Eximo Medical Ltd., into its product portfolio.
Strategic Position & Investments
AngioDynamics’ strategic direction centers on accelerating growth in higher-margin, technology-driven platforms while improving operational efficiency across its legacy product lines. Key growth initiatives include expanding adoption of its NanoKnife® IRE System for tumor ablation and scaling its AngioVac® and thrombectomy platforms in venous disease and pulmonary embolism treatment.
The company has pursued selective acquisitions to strengthen its technology base, including the acquisition of Eximo Medical Ltd., which expanded its peripheral vascular intervention capabilities. AngioDynamics continues to invest in clinical trials, regulatory approvals, and physician education to support emerging therapeutic applications, while divesting or deemphasizing lower-growth product categories where appropriate.
Geographic Footprint
AngioDynamics is headquartered in Latham, New York, and maintains a significant operational presence across North America and Europe. The United States represents its largest market, accounting for the majority of revenue, supported by a direct sales force and domestic manufacturing and distribution infrastructure.
Internationally, the company operates in Europe, Asia-Pacific, and selected markets in Latin America through a mix of direct subsidiaries and third-party distributors. Its global footprint allows it to participate in international clinical studies and regulatory pathways, supporting broader adoption of its technologies outside the U.S.
Leadership & Governance
AngioDynamics is led by an executive team with experience in medical devices, healthcare operations, and corporate strategy. The leadership emphasizes disciplined capital allocation, innovation-driven growth, and improving profitability through operational execution and portfolio focus.
Key executives include:
- James L. Clemmer – President and Chief Executive Officer
- Robert S. McDermott – Executive Vice President and Chief Financial Officer
- Aaron M. Hockley – Executive Vice President and General Counsel
- Theresa P. Taylor – Executive Vice President, Global Human Resources
- Suresh V. Patel – Executive Vice President, Operations and Supply Chain
The board of directors provides oversight aligned with shareholder interests, regulatory compliance, and long-term value creation, with governance practices consistent with publicly listed U.S. medical technology companies.